Conference Coverage

Delaying Adalimumab Tx Impairs Long-Term Response

Publish date: July 6, 2012

 

AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

Dr. Keystone disclosed financial relationships with Abbott, Amgen, AstraZeneca, Biotest, Bristol-Myers Squibb, Centocor, Genentech, Genzyme, Merck, Novartis, Nycomed, Pfizer, Roche, and UCB.

Pages

Recommended Reading

Is Tocilizumab Monotherapy for RA Losing Luster?
MDedge Rheumatology
Small Study: Reduced Anti-TNF Dose Still Effective
MDedge Rheumatology
New JAK Inhibitors Show RA Safety, Efficacy
MDedge Rheumatology
Synovitis in RA Identifies High Progression Risk
MDedge Rheumatology
High Interferon Response, Low B Cells Presage Rheumatoid Arthritis
MDedge Rheumatology
Tocilizumab Beats Adalimumab in Monotherapy RA Trial
MDedge Rheumatology
VTE Risk Pumped Up in Rheumatoid Arthritis
MDedge Rheumatology
FDA Panel Considers Metal-on-Metal Hip Replacements
MDedge Rheumatology
Psoriatic Arthritis Screening Tests Deemed Inadequate
MDedge Rheumatology
New Biomarkers Identify Tocilizumab Responders Super Early
MDedge Rheumatology